Akademisyen
LEYLA YURTTAŞ
PROFESÖR
ANADOLU ÜNİVERSİTESİ ECZACILIK FAKÜLTESİ ECZACILIK MESLEK BİLİMLERİ BÖLÜMÜ
- Ana Dal Sağlık Bilimleri Temel Alanı
- Yan Dal Farmasotik Kimya
Kayıtlı çıktılara kısa bakış — ayrıntılar aşağıda.
- Makale 138
- Proje 0
- Kitap 4
- Bildiri 72
- Patent 0
- Sanatsal 0
Scopus (SJR)
Q1
18
Q2
50
Q3
32
Q4
15
WoS (JCR)
Q1
14
Q2
29
Q3
33
Q4
40
TR Index
15
makale
Alan+yıl+tür normalize OpenAlex yüzdelik — Clarivate ESI / SciVal değildir.
Üst %1 makale
0
Üst %10 makale
12
Ort. yüzdelik
67.8%
Üst %1 payı
0.0%
Üst %10 payı
11.5%
Makaleler
YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.
Makale listesi
- 2025 Investigation of novel imidazo[1,2-a]pyrazine derivatives as antiproliferative agents and their enzymatic inhibition effect against MMP-9 YÖKSİS SJR Q4 JCR Q3 OpenAlex 10.2%
- 2025 Novel thiazole based 4-nitrosalicyl hydrazone derivatives as anticancer agents YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 93.1%
- 2025 New benzothiazole-hydrazone derivatives: Antimicrobial and cytotoxic evaluation YÖKSİS SJR Q4 JCR Q3 OpenAlex 9.9%
- 2025 Cyclooxygenase Inhibitor 4‐Methylthiazole Derivative Compound Alleviates Lipopolysaccharides‐Induced Neuroinflammation in Male Rats With Regulating Cytokine Levels YÖKSİS SJR Q2 JCR Q2 OpenAlex 76.3%
- 2025 Novel pyridine-thiazole hybrid: synthesis, structural characterisation and adme predictions YÖKSİS OpenAlex 61.1%
- 2025 Synthesis of new dihydropyrimidine derivatives and investigation of their antimicrobial and DNA gyrase inhibitory activities YÖKSİS SJR Q2 JCR Q2 OpenAlex 85.7%
- 2025 Development and Biological Assessment of Thiazole-Based Pyridines for Targeted Therapy in Lung Cancer YÖKSİS SJR Q1 JCR Q2 OpenAlex 89.9%
- 2025 Pharmacophore‐Based Modeling, Synthesis, and Biological Evaluation of Novel Quinazoline/Quinoline Derivatives: Discovery of EGFR Inhibitors with Low Nanomolar Activity YÖKSİS SJR Q1 JCR Q2 OpenAlex 85.8%
- 2025 Synthesis, molecular docking, and molecular dynamic simulation studies of new 1,3,4-thiadiazole derivatives as potential apoptosis inducers in A549 lung cancer cell line YÖKSİS SJR Q2 JCR Q3 OpenAlex 84.4%
- 2025 Novel Metronidazole Conjugates as Antimicrobial Agents YÖKSİS SJR Q2 JCR Q2 OpenAlex 88.6%
- 2025 Exploring Novel Quinoline-1,3,4-Oxadiazole Derivatives for Alzheimer’s Disease: Their Design, Synthesis, and In-Vitro and In-Silico Investigations YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 91.7%
- 2025 Evaluation of the Antileishmanial Activity of Some Benzimidazole Derivatives Using In Vitro and In Silico Techniques YÖKSİS SJR Q1 JCR Q1
- 2025 Design and synthesis of new benzothiazole-piperazine derivatives and in vitro and in silico investigation of their anticancer activity YÖKSİS SJR Q2 JCR Q2 OpenAlex 81.7%
- 2025 Latest developments in small molecule analgesics: heterocyclic scaffolds I. YÖKSİS SJR Q3 JCR Q3 OpenAlex üst %10 OpenAlex 93.6%
- 2025 Design, synthesis of novel thiazole‐thiomorpholine derivatives and evaluation of their anticancer activity via in vitro and in silico studies YÖKSİS SJR Q2 JCR Q2 OpenAlex 77.6%
- 2024 Synthesis, characterization, molecular docking and molecular dynamics simulations of novel 2,5-disubstituted-1,3,4-thiadiazole derivatives as potential cholinesterase/monoamine oxidase dual inhibitors for Alzheimer’s disease YÖKSİS SJR Q2 JCR Q3 OpenAlex üst %10 OpenAlex 91.4%
- 2024 Design, Synthesis, and Biological Effect Studies of Novel Benzofuran–Thiazolylhydrazone Derivatives as Monoamine Oxidase Inhibitors YÖKSİS SJR Q1 JCR Q2 OpenAlex 56.1%
- 2024 Design and synthesis of phenoxy methyl‐oxadiazole compounds against Alzheimers disease YÖKSİS SJR Q2 JCR Q2 OpenAlex üst %10 OpenAlex 93.3%
- 2024 Design and synthesis of novel dithiazole carboxylic acid Derivatives: In vivo and in silico investigation of their Anti-Inflammatory and analgesic effects YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 94.4%
- 2024 Synthesis and anticancer activity evaluation of some novel imidazo[1,2-a]pyridine based heterocycles containing S-alkyl/aryl moiety YÖKSİS SJR Q4 JCR Q3 OpenAlex 63.4%